You are here

BCRF Grantee Since


Donor Recognition

The Estée Lauder Companies Brands Award in Memory of Evelyn H. Lauder

Area(s) of Focus

Fabrice Andre, MD, PhD

Research Director, Head of INSERM Unit U981
INSERM (Institut National des Sciences et de la Recherche Médicale)
Associate Professor, Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France

Current Research

Each breast cancer is characterized by a unique pattern of genomic alterations. Targeting the genomic alteration responsible for transforming cells from benign to malignant should stop cancer progression, but some studies suggest that such targeted treatments may lead to drug resistance in some breast cancer patients. The goal of Dr. André’s BCRF project is to identify genetic biomarkers associated with resistance to targeted therapies in metastatic breast cancer. His group is analyzing the DNA from patients who have been treated with a gene-targeted therapy to determine whether multiple DNA mutations within the different tumor cells make the tumors resistant to therapy. Dr. André will test his findings in patient samples from a randomized clinical trial to evaluate whether the genomic alterations predict response to targeted therapies. These studies will lead to better personalized therapies by identifying new genes involved in the development of breast cancer and potential drug combinations most likely to work in a specific subset of breast cancer patients.


Fabrice André is a medical oncologist and PhD based at Gustave Roussy Cancer Center, Villejuif, France. He is professor of medicine at University Paris Sud. His main research interest is the development of clinical trials in the field of personalized medicine for breast cancer. He is leading a research laboratory working on the identification of new targets and biomarkers (INSERM Unit U981), and also is leading the Personalized Medicine Group at the French Federation of Cancer Centers (UNICANCER). He is a member of the executive board of Breast International Group (BIG). He is Senior Associate Editor, Breast Cancer, for Annals of Oncology.